Ser159

Site Information
YQGGNGssPVRGIPP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 449213

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 )
Disease tissue studied:	breast cancer ( 7 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , cervical cancer ( 17 ) , cervical adenocarcinoma ( 17 ) , leukemia ( 23 ) , chronic myelogenous leukemia ( 23 ) , lung cancer ( 7 ) , non-small cell lung cancer ( 7 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	'stem, embryonic' ( 19 ) , 293E (epithelial) ( 11 ) , A549 (pulmonary) ( 5 ) , breast ( 1 ) , BT-20 (breast cell) ( 7 ) , BT-549 (breast cell) ( 7 ) , Calu 6 (pulmonary) ( 7 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 8 ) , Flp-In T-Rex-293 (epithelial) ( 8 ) , GM00130 (B lymphocyte) ( 16 ) , H2077 (pulmonary) ( 7 ) , H322M (pulmonary) ( 7 ) , HCC366 (pulmonary) ( 7 ) , HCC78 (pulmonary) ( 7 ) , HCT116 (intestinal) ( 20 ) , HeLa (cervical) ( 3 , 6 , 13 , 14 , 24 , 26 ) , HeLa S3 (cervical) ( 17 ) , HeLa_Meta (cervical) ( 15 ) , HeLa_Pro (cervical) ( 15 ) , HeLa_Telo (cervical) ( 15 ) , HOP62 (pulmonary) ( 7 ) , HUES-7 ('stem, embryonic') ( 18 ) , HUES-9 ('stem, embryonic') ( 12 ) , Jurkat (T lymphocyte) ( 10 , 21 , 22 ) , K562 (erythroid) ( 6 , 23 ) , MDA-MB-231 (breast cell) ( 7 ) , MDA-MB-435S (breast cell) ( 20 ) , MDA-MB-468 (breast cell) ( 7 ) , MV4-11 (macrophage) ( 20 ) , NCI-H1395 (pulmonary) ( 7 ) , NCI-H157 (pulmonary) ( 7 ) , NCI-H1648 (pulmonary) ( 7 ) , NCI-H1666 (pulmonary) ( 7 ) , NCI-H2030 (pulmonary) ( 7 ) , NCI-H322 (pulmonary) ( 7 ) , NCI-H520 (squamous) ( 7 ) , PANC-1 (pancreatic) [PRP4 (human), knockdown, Lentiviral introduced doxycycline-inducible PRP4 shRNA] ( 4 ) , PANC-1 (pancreatic) ( 4 ) , PC9 (pulmonary) ( 7 ) , U2OS (bone cell) [GR (human)] ( 25 ) , WM239A (melanocyte) ( 2 )

Upstream Regulation
Regulatory protein:	PRP4 (human) ( 4 )
Treatments:	MG132_withdrawal ( 15 ) , nocodazole ( 17 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
4	Gao Q, et al. (2013) Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches. J Biol Chem 288, 30125-38 24003220 Curated Info
5	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
6	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
7	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
8	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
9	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
10	Mulhern D (2011) CST Curation Set: 12711; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Curated Info
11	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
12	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
13	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
14	Hegemann B, et al. (2011) Systematic phosphorylation analysis of human mitotic protein complexes. Sci Signal 4, rs12 22067460 Curated Info
15	Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81 20097925 Curated Info
16	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
17	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
18	Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26 19664995 Curated Info
19	Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13 19664994 Curated Info
20	Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64 19369195 Curated Info
21	Possemato A (2009) CST Curation Set: 6369; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
22	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
23	Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
24	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info
25	Lowery DM, et al. (2007) Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J 26, 2262-73 17446864 Curated Info
26	Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5 15302935 Curated Info